Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.